Advancing a novel product pipeline of neurology therapies

View Product Pipeline

Advancing a novel product pipeline of neurology therapies

View Product Pipeline
About

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.

Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.

 

Reminder: Xenon’s Annual Meeting of Shareholders will take place on Thursday, June 3, 2021 at 11:30 am PT / 2:30 pm ET. See more details here.
Read More

Product Pipeline


Preclinical
Phase 1
Phase 2
Phase 3
Approved

XEN1101

for Epilepsy
X-TOLE Clinical Trial

XEN1101

for MDD
Collaboration with Mount Sinai

XEN496

for Epilepsy
EPIK Clinical Trial

XEN007

for Orphan Neurological Indications
Investigator-Led Study in CAE

NBI-921352

for Epilepsy
Partnered with Neurocrine Biosciences

FX301

for Post-Operative Pain
Partnered with Flexion Therapeutics

NAV1.7 Inhibitors

for Pain
Partnered with Genentech

* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).


Investors

Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events

View Investor Area
Our Management

Learn more about Xenon's management group

View Management
Careers

See current career opportunities

View Careers